Scientists discover new method of predicting response to chemotherapy in bowel cancer

January 18, 2013

Scientists at the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital have developed a new method of predicting which patients with bowel (colorectal) cancer will respond effectively to chemotherapy. The results of this study are published in the current issue of the prestigious Cancer Research journal.

The discovery could, in the future, help identify individuals who will not respond to , before they commence treatment, and may therefore require additional therapies. The new tool measures the amount of drug required for a cancer cell to die without harming healthy tissue. This prediction tool may also be used in clinical trails to develop new drugs to treat bowel cancer.

Commenting on the results, lead researcher, Professor Jochen Prehn, Director of the Centre for Systems Medicine at RCSI said: "Our study has enabled us to predict which patients are likely to be resistant to chemotherapy by examining how certain proteins in their cancer cells interact. We hope that the -making tool that we have designed will enable doctors to develop personalised therapies for patients to ensure the best outcomes and potentially avoiding unnecessary chemotherapy and the negative side effects that go with it."

Chemotherapy destroys cancer cells by bringing on a process of , known as apoptosis. However, sometimes mutations in cancer cells alter the levels of certain proteins and prevent this process of cell death occurring which results in chemotherapy being ineffective in some individuals with bowel cancer. In other patients, mutations in cancer cells have the opposite effect and promote the destruction of the .

"The prediction tool also has the potential to be used in clinical trials so that can be developed for bowel who are resistant to chemotherapy. The model we developed in this study could eventually be applied in other cancers." Professor Prehn concluded.

The first author on the study is Andreas Linder, a PhD researcher who carried out the research with Professor Prehn and RCSI colleagues (Dr. Caoimhin Concannon, Dr. Gerhardt Boukes, Dr. Suzanne Hector, Dr. Heinrich Huber) in collaboration with clinicians (Deborah Ryan, Mary Cannon, Karen Boland, Ms. Deborah McNamara, Professor Elaine Kay, Prof Frank Murray) and research nurse Joan Kehoe at Beaumont Hospital, Dublin, and collaborators at St. Jude's Children's Research Hospital, Memphis, Tennessee (Dr Fabien Llambi and Professor Douglas Green).

is the second most common cancer in Ireland. In 2009, 2,271 people were diagnosed with the disease. It is also the second most common cause of cancer death in Ireland.

Explore further: New model may help predict response to chemotherapy for colorectal cancer

More information: Systems Analysis of BCL2 Protein Family Interactions Establishes a Model to Predict Responses to Chemotherapy, Andreas U. Lindner, Caoimhín G. Concannon, Gerhardt J. Boukes, Mary D. Cannon, Fabien Llambi, Deborah Ryan, Karen Boland, Joan Kehoe, Deborah A. McNamara, Frank Murray, Elaine W. Kay, Suzanne Hector, Douglas R. Green, Heinrich J. Huber, and Jochen H.M. Prehn, Cancer Res, January 15, 2013 73:2 519-528; doi:10.1158/0008-5472.CAN-12-2269

Related Stories

New model may help predict response to chemotherapy for colorectal cancer

January 17, 2013
Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the amount of stress required for a cancer cell to die without harming ...

New type of molecular switch could turn up the volume on bowel cancer treatment

November 5, 2012
(Medical Xpress)—A new type of molecular switch can boost common chemotherapy drugs to destroy bowel cancer cells, according to research presented today (Monday) at the NCRI Cancer Conference in Liverpool.

Latest research shows how cancer cells react to chemotherapy

July 14, 2011
EU-funded researchers have made good progress in understanding how cancer cells can sometimes resist the effects of chemotherapy. This new knowledge will move forward the development of increasingly effective cancer treatments ...

Researchers investigate drug resistant ovarian cancer to improve clinical treatment

August 9, 2012
(Medical Xpress) -- A new study by TCD researchers investigates drug-resistant ovarian cancer cells. The findings which have been recently published in the international publication, PLoS One will increase understanding of ...

Trial launched into curry chemical's cancer-fighting properties

May 7, 2012
Compounds found in curry are being investigated as a way of improving drug response in patients with advanced bowel cancer in a new study launched today (Monday).

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.